#AS­CO21: Co­herus, Jun­shi hunt US ap­proval for an­ti-PD-1 drug in nose and throat can­cer with late-stage win

The an­ti-PD-1/L1 mar­ket has grown in­creas­ing­ly packed in re­cent years with a slate of late ad­di­tions look­ing to carve out mar­ket share. A Chi­nese com­peti­tor from Jun­shi Bio­sciences and Co­herus is laser fo­cus­ing on a pre­dom­i­nant­ly South­east Asian pa­tient pop­u­la­tion, and its re­sults there could be strong enough to pave a path to ap­proval in the US.

Co­herus and Jun­shi’s tori­pal­imab added to first-line chemother­a­py in na­sopha­ryn­geal can­cer hits its marks in pro­gres­sion-free sur­vival over chemo alone, adding some heft to the Chi­nese-made mol­e­cule’s chances at the US mar­ket, ac­cord­ing to late break­ing da­ta set to be pre­sent­ed at this week­end’s #AS­CO21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.